MPI Research, the largest single-site preclinical contract research organization worldwide, is pleased to announce that Alan P. Breau, PhD, has joined the company as Vice President of its Bioanalytical and Analytical Services (B/AS) division. B/AS is one of the three core research divisions at MPI Research, along with Drug Safety Evaluation and Discovery Services.
Dr. Breau is a recognized expert in mass spectrometry, metabolite identification, pharmacokinetics, and bioanalytical chemistry. He is a cofounder of the Consortium for Metabonomic Toxicology (COMET) and established a metabonomics group that provided toxicity assessments and biomarker support. With over 30 years of rich and varied scientific experience in the biopharmaceutical industry, Dr. Breau has served as a consultant (IDSC Biotech Network), Senior Director of DMPK and Bioanalytical Chemistry (Metabasis Therapeutics, Inc.), Senior Director of Analytical Sciences (Theravance, Inc.), Research Fellow (Amgen, Inc.), Director of Pharmacokinetics and Bioanalytical Chemistry (Searle/Pharmacia/Pfizer), Director of Analytical Chemistry/Mass Spectrometry (Searle/Monsanto), Product Applications Lab Manager (Applied Biosystems), Senior Scientist (Allergan), and Senior Pharmacologist (Eli Lilly). Dr. Breau completed his undergraduate degree in chemistry at the Massachusetts Institute of Technology, did his post-doctoral fellowship with Harvard University and received his PhD in pharmacology from Vanderbilt University.
Dr. Tina Rogers, PhD, MBA, DABT, Director of Research and Executive Vice President at MPI Research, states, “Joining Drs. David Laveglia and Glenn Smits, Dr. Breau is an excellent addition to the MPI Research leadership team that is responsible for directing the company’s three core research divisions. Our ability to meet the bioanalytical and analytical needs of our Sponsors is further strengthened by Dr. Breau’s depth of experience and strategic acumen.”
MPI Research, with global headquarters in Mattawan, Michigan, provides discovery, safety evaluation, bioanalytical, and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries. Scientific knowledge and experience, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world. Learn more about how we can exceed your expectations at www.mpiresearch.com.
Kallik’s new approach to asset management delivers long term artwork automisation
Marketing and compliance departments can now have greater control over their assets –from logos and images to labelling copy – and a roadmap to automated artwork generation, thanks to Kallik’s online Asset Repository. It is the most cost-effective way to lay the foundation for future automisation of the artwork and labelling generation. The practice of centralising the content in a web-based asset library and reusing those assets across all marketing and trade communications is saving businesses thousands, if not millions, of pounds. More info >>
